Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...

We expect investors to focus on updates related to Viking Therapeutics’ VKTX pipeline when it reports first-quarter 2025 results on April 23, after market close. In the last reported quarter ...

A major C-suite change at a potential competitor was a key factor behind the rise of Viking Therapeutics (NASDAQ: VKTX) stock on Friday, which closed the trading session 3% higher. That figure was ...

Investors looking to cash in on the fast-growing market for weight management medicines will naturally turn to the two ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Viking Therapeutics wasn’t one of them. The 10 stocks that ...

One of the best catalysts for a stock's rise is the withdrawal of a rival. That was an important dynamic behind the double-digit-percentage rise of biotech Viking Therapeutics ' ( VKTX 3.61%) stock in ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Viking Therapeutics wasn’t one of them. The 10 stocks that ...

That's a tall ask, considering that failing its clinical trials could wipe out the stock's value. A wide range of investment outcomes means that Viking Therapeutics may not be suitable for everyone.

Viking Therapeutics (NASDAQ: VKTX), a biotech that has shot to prominence thanks to a weight-loss drug it is developing, was a winning stock this week. Over the course of the past five trading ...